Online inquiry

IVTScrip™ pT7-VEE-mRNA-Anti-CA9, 124I_WX-G250 Vector   (CAT#: GTVCR-WQ31MR)

This product GTVCR-WQ31MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the T7 promoter to efficiently generate mRNA ecoding antibody which targeting CA9. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter T7
Resistance Ampicillin
Species Chimeric
RefSeq NM_001216.3
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 768
UniProt ID Q16790
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pT7-VEE-mRNA-Anti-CA9, 124I_WX-G250 Vector (GTVCR-WQ31MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ1710MR IVTScrip™ pSP6-VEE-mRNA-Anti-ITGA4&ITGB7, LDP-02 Vector Vector LDP-02
GTVCR-WQ1061MR IVTScrip™ pSP6-VEE-mRNA-Anti-TNFRSF10B, CS-1008 Vector Vector CS-1008
GTVCR-WQ1333MR IVTScrip™ pSP6-VEE-mRNA-Anti-ICOS, GSK-3359609 Vector Vector GSK-3359609
GTVCR-WQ769MR IVTScrip™ pSP6-VEE-mRNA-Anti-CXCR4, BMS-936564 Vector Vector BMS-936564
GTVCR-WQ2424MR IVTScrip™ pT7-VEE-mRNA-Anti-CNR1, RYI-018 Vector Vector RYI-018
GTVCR-WQ296MR IVTScrip™ pT7-VEE-mRNA-Anti-CD40, ADC-1013 Vector Vector ADC-1013
GTVCR-WQ122MR IVTScrip™ pSP6-VEE-mRNA-Anti-CD276, 8H9 Vector Vector 8H9
GTVCR-WQ1005MR IVTScrip™ pSP6-VEE-mRNA-Anti-IL6, CLLB8 Vector Vector CLLB8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW